CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Prostate Biopsy Specimen Analysis

Customize your policy alerts

Sign up for all blue cross blue shield - tennessee policy alerts

Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Covers pathological examination of prostate biopsy specimens for diagnosis, staging, and management of prostate cancer; applies to Blue Cross Blue Shield - Tennessee members and providers submitting claims for prostate biopsy pathology services.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prostate biopsy specimens with one vial per sextant and no more than two core samples per vial and report using appropriate pathology codes such as 88305 or G0416.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12-coreextended sampling specified for initial diagnosis

1 vial per sextantspecimen handling instruction

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Prostate Biopsy Specimen Analysis

Customize your policy alerts

Sign up for all blue cross blue shield - tennessee policy alerts

Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyProstate Biopsy Specimen Analysis

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prostate biopsy specimens with one vial per sextant and no more than two core samples per vial and report using appropriate pathology codes such as 88305 or G0416.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

12-coreextended sampling specified for initial diagnosis

1 vial per sextantspecimen handling instruction

Coverage Criteria

Medically Necessary Indications

Covered when ALL of the following are met:

Initial diagnosis: Pathological examination of tissue obtained from a prostate biopsy involving 12-core extended sampling meets coverage criteria when performed as follow-up to abnormal PSA results, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.12 cores

See Note 1: one vial per sextant, no more than two cores per vial.

Repeat biopsy after negative initial: Pathological examination of tissue from a follow-up prostate biopsy meets coverage criteria when clinical suspicion for prostate cancer remains after an initial negative biopsy (excludes prostate saturation biopsy).exclude saturation biopsy

Pathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria. The policy excludes saturation biopsy pathology from coverage because there is a lack of available published scientific literature demonstrating that the procedure is required and beneficial for the diagnosis, staging, or management of prostate cancer. As a result, claims for pathological examination of specimens from saturation biopsies may be denied.

Prostate saturation biopsy pathology is considered not medically necessary because the policy states there is insufficient published scientific evidence to confirm that the test provides benefit for diagnosis, staging, or management of prostate cancer. Coverage is limited to defined biopsy approaches with established evidence (for example, 12-core extended sampling and certain follow-up biopsies); saturation biopsy falls outside those covered indications and is explicitly excluded.

Applicable CPT/HCPCS Procedure Codes

Applicable CPT/HCPCS Procedure Codesmixed

88305	Level IV - Surgical pathology, gross and microscopic examination.
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

Applicable CPT/HCPCS Procedure Codes (duplicate group for clarity)mixed

88305	Level IV - Surgical pathology, gross and microscopic examination.
G0416	Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method

Provider Actions and Billing Guidance

Note

Coverage requirement for prostate biopsy pathology

Pathological examination of prostate biopsy specimens is covered when performing a 12-core extended sampling for initial diagnosis, and for follow-up prostate biopsies after an initial negative biopsy (excluding saturation biopsy).

Coverage applies to 12-core extended sampling for initial diagnosis.
Coverage applies to follow-up prostate biopsies after an initial negative biopsy (prostate saturation biopsy is excluded).

Documentation Required

Provider documentation and actions

Submit specimens labeled by sextant and follow facility-specific documentation standards. Ensure clinical documentation supports the indication for biopsy (e.g., abnormal PSA, palpable nodule, or suspicious imaging) is available in the medical record.

Document indication for biopsy (abnormal PSA, palpable nodule, or suspicious radiologic findings).

Background

Prostate cancer spans a spectrum from indolent, microscopic disease to aggressive high-grade tumors. Initial diagnostic indications for prostate biopsy pathology include an abnormal prostate-specific antigen (PSA), a palpable nodule on digital rectal examination, or suspicious radiologic findings. Pathologic examination of biopsy tissue is used to confirm diagnosis and guide management; the policy covers 12-core extended sampling for initial diagnosis and certain follow-up biopsies when clinical suspicion persists, but excludes saturation biopsy pathology due to insufficient evidence.

Definitions

Prostate cancer — key facts

DefinitionMalignancy of the prostate gland that ranges from microscopic, well-differentiated tumors to aggressive high-grade cancer.

Clinical significanceDisease spectrum varies from indolent tumors that may never be clinically significant to aggressive cancers requiring intervention.

Common diagnostic rolePathologic examination of prostate biopsy tissue is used to confirm diagnosis, stage disease, and guide management.

Prostate saturation biopsy — definition and policy

DefinitionSaturation biopsy: an extensive sampling technique of the prostate that obtains multiple cores beyond standard extended (12-core) sampling.

Policy stancePathological examination of tissue obtained from a prostate saturation biopsy does not meet coverage criteria and is considered not medically necessary.